BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9765760)

  • 1. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
    Figueredo A; Germond C; Maroun J; Browman G; Walker-Dilks C; Wong S
    Cancer Prev Control; 1997 Dec; 1(5):379-92. PubMed ID: 9765760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
    Figueredo A; Fine S; Maroun J; Walker-Dilks C; Wong S
    Cancer Prev Control; 1997 Oct; 1(4):304-19. PubMed ID: 9765754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group.
    Whelan TJ; Lada BM; Laukkanen E; Perera FE; Shelley WE; Levine MN
    Cancer Prev Control; 1997 Aug; 1(3):228-40. PubMed ID: 9765748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
    Lopez PG; Stewart DJ; Newman TE; Evans WK
    Cancer Prev Control; 1997; 1(1):18-27. PubMed ID: 9765723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group.
    Goss GD; Logan DM; Newman TE; Evans WK
    Cancer Prev Control; 1997; 1(1):28-38. PubMed ID: 9765724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline.
    Jonker DJ; Spithoff K; Maroun J;
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):314-22. PubMed ID: 21397476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Goss G; Paszat L; Newman TE; Evans WK; Browman G
    Cancer Prev Control; 1998 Feb; 2(1):32-9. PubMed ID: 9765764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group.
    Mirsky D; O'Brien SE; McCready DR; Newman TE; Whelan TJ; Levine MN
    Cancer Prev Control; 1997; 1(1):10-7. PubMed ID: 9765722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication.
    Skillings JR; Levine M; Rayner HL; Eisenhauer E; Erlichman C; Germond C; Kerr I; Lofters W; Maroun J; Yoshida S
    CMAJ; 1991 Feb; 144(3):297-301. PubMed ID: 1989708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
    Benson AB
    Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
    J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.